AEROSPORIN Drug Patent Profile
✉ Email this page to a colleague
When do Aerosporin patents expire, and when can generic versions of Aerosporin launch?
Aerosporin is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in AEROSPORIN is polymyxin b sulfate. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aerosporin
A generic version of AEROSPORIN was approved as polymyxin b sulfate by ADRASTEA PHARMA on September 30th, 1994.
Summary for AEROSPORIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Patent Applications: | 18 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AEROSPORIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AEROSPORIN
US Patents and Regulatory Information for AEROSPORIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | AEROSPORIN | polymyxin b sulfate | INJECTABLE;INJECTION | 062036-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |